---
title: "Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285701382.md"
description: "Barclays analyst Eliana Merle has maintained a Buy rating on Madrigal Pharmaceuticals (MDGL) with a price target of $964.00. Merle, a 3-star analyst, has an average return of 3.8% and a 41.22% success rate. Additionally, H.C. Wainwright's Andrew Fein also issued a Buy rating for the company, while Bank of America Securities reiterated a Hold rating on the same day."
datetime: "2026-05-08T09:55:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285701382.md)
  - [en](https://longbridge.com/en/news/285701382.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285701382.md)
---

# Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays

In a report released today, Eliana Merle from Barclays maintained a Buy rating on Madrigal Pharmaceuticals, with a price target of $964.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Merle is a 3-star analyst with an average return of 3.8% and a 41.22% success rate. Merle covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BridgeBio Pharma, and BioMarin Pharmaceutical.

In addition to Barclays, Madrigal Pharmaceuticals also received a Buy from H.C. Wainwright’s Andrew Fein in a report issued yesterday. However, on the same day, Bank of America Securities reiterated a Hold rating on Madrigal Pharmaceuticals (NASDAQ: MDGL).

### Related Stocks

- [MDGL.US](https://longbridge.com/en/quote/MDGL.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [ALNY.US](https://longbridge.com/en/quote/ALNY.US.md)
- [BBIO.US](https://longbridge.com/en/quote/BBIO.US.md)
- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [What Madrigal Pharmaceuticals (MDGL)'s Wider Q1 Losses and Rezdiffra Revenue Momentum Mean For Shareholders](https://longbridge.com/en/news/286674743.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Corvus Pharmaceuticals presents Phase 1 soquelitinib data showing durable remissions, favorable safety](https://longbridge.com/en/news/286404245.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Eton Pharmaceuticals Q1 product sales rise driven by portfolio expansion](https://longbridge.com/en/news/286461579.md)